Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Hearing Disorders: HELP
Articles by Neil Marlow
Based on 4 articles published since 2010
(Why 4 articles?)
||||

Between 2010 and 2020, Neil Marlow wrote the following 4 articles about Hearing Disorders.
 
+ Citations + Abstracts
1 Clinical Trial Pilot evaluation of the population pharmacokinetics of bumetanide in term newborn infants with seizures. 2016

Jullien, Vincent / Pressler, Ronit M / Boylan, Geraldine / Blennow, Mats / Marlow, Neil / Chiron, Catherine / Pons, Gerard / Anonymous6200836. ·INSERM U1129 "Infantile Epilepsies and Brain Plasticity," Paris, France; Paris Descartes University; CEA, Gif sur Yvette, France. · Service de Pharmacologie, Hôpital Européen Georges Pompidou, Assistance Publique Hôpitaux de Paris, Paris, France. · Neuroscience Unit (ICH) and Neonatal Unit (IWH), University College London, London, UK. · INFANT Research Centre & Neonatal Intensive Care Unit, University College Cork, Cork, Ireland. · Neonatology, Karolinska Institutet and University Hospital, Stockholm, Sweden. ·J Clin Pharmacol · Pubmed #26189501.

ABSTRACT: Recent experimental data suggest bumetanide as a possible therapeutic option in newborn infants with seizures after birth asphyxia. Because pharmacokinetic (PK) data are lacking in this population, who very often benefit from therapeutic cooling, which can modify the PK behavior of a drug, a PK study was conducted in term infants with seizures caused by hypoxic-ischemic encephalopathy. Fourteen infants were included, 13 of them being cooled. Forty-nine blood samples were available for the determination of the plasma concentration of bumetanide. Concentration-time data were analyzed by the use of a population approach performed with Monolix Software. Bumetanide was found to follow a 2-compartment model. The mean values were 0.063 L/h for clearance, 0.28 and 0.44 L for the central and peripheral distribution volumes, respectively, and 0.59 L/h for the distribution clearance. Birth body weight explained the interindividual variability of bumetanide clearance via an allometric model. No relationship was found between bumetanide exposure and its efficacy (reduction in seizure burden) or its toxicity (hearing loss). This study describes the first PK model of bumetanide in hypothermia-treated infants with seizures.

2 Article Association Between Oxygen Saturation Targeting and Death or Disability in Extremely Preterm Infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration. 2018

Askie, Lisa M / Darlow, Brian A / Finer, Neil / Schmidt, Barbara / Stenson, Ben / Tarnow-Mordi, William / Davis, Peter G / Carlo, Waldemar A / Brocklehurst, Peter / Davies, Lucy C / Das, Abhik / Rich, Wade / Gantz, Marie G / Roberts, Robin S / Whyte, Robin K / Costantini, Lorrie / Poets, Christian / Asztalos, Elizabeth / Battin, Malcolm / Halliday, Henry L / Marlow, Neil / Tin, Win / King, Andrew / Juszczak, Edmund / Morley, Colin J / Doyle, Lex W / Gebski, Val / Hunter, Kylie E / Simes, Robert J / Anonymous4020950. ·National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia. · Department of Paediatrics, University of Otago, Christchurch, New Zealand. · Department of Pediatrics, University of California, San Diego. · Division of Neonatology, University of Pennsylvania, Philadelphia. · Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada. · Department of Neonatology, Royal Infirmary of Edinburgh, Edinburgh, Scotland. · Newborn Research, Royal Women's Hospital, Departments of Obstetrics and Gynaecology, and Paediatrics, University of Melbourne, Melbourne, Australia. · Clinical Sciences, Murdoch Children's Research Institute, Melbourne, Australia. · Department of Pediatrics, University of Alabama, Birmingham. · Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, England. · National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, England. · Statistics and Epidemiology Unit, RTI International, Rockville, Maryland. · Statistics and Epidemiology Unit, RTI International, Research Triangle Park, North Carolina. · Department of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada. · Department of Neonatology, Tuebingen University Hospital, Tuebingen, Germany. · Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada. · Newborn Services, Auckland City Hospital, Auckland, New Zealand. · Royal Maternity Hospital, Belfast, Ireland. · Department of Child Health, Queen's University, Belfast, Ireland. · EGA Institute for Women's Health, University College London, London, England. · Department of Neonatal Medicine, James Cook University, Middlesbrough, England. · University of Cambridge, Department of Obstetrics and Gynaecology, Cambridge, England. ·JAMA · Pubmed #29872859.

ABSTRACT: Importance: There are potential benefits and harms of hyperoxemia and hypoxemia for extremely preterm infants receiving more vs less supplemental oxygen. Objective: To compare the effects of different target ranges for oxygen saturation as measured by pulse oximetry (Spo2) on death or major morbidity. Design, Setting, and Participants: Prospectively planned meta-analysis of individual participant data from 5 randomized clinical trials (conducted from 2005-2014) enrolling infants born before 28 weeks' gestation. Exposures: Spo2 target range that was lower (85%-89%) vs higher (91%-95%). Main Outcomes and Measures: The primary outcome was a composite of death or major disability (bilateral blindness, deafness, cerebral palsy diagnosed as ≥2 level on the Gross Motor Function Classification System, or Bayley-III cognitive or language score <85) at a corrected age of 18 to 24 months. There were 16 secondary outcomes including the components of the primary outcome and other major morbidities. Results: A total of 4965 infants were randomized (2480 to the lower Spo2 target range and 2485 to the higher Spo2 range) and had a median gestational age of 26 weeks (interquartile range, 25-27 weeks) and a mean birth weight of 832 g (SD, 190 g). The primary outcome occurred in 1191 of 2228 infants (53.5%) in the lower Spo2 target group and 1150 of 2229 infants (51.6%) in the higher Spo2 target group (risk difference, 1.7% [95% CI, -1.3% to 4.6%]; relative risk [RR], 1.04 [95% CI, 0.98 to 1.09], P = .21). Of the 16 secondary outcomes, 11 were null, 2 significantly favored the lower Spo2 target group, and 3 significantly favored the higher Spo2 target group. Death occurred in 484 of 2433 infants (19.9%) in the lower Spo2 target group and 418 of 2440 infants (17.1%) in the higher Spo2 target group (risk difference, 2.8% [95% CI, 0.6% to 5.0%]; RR, 1.17 [95% CI, 1.04 to 1.31], P = .01). Treatment for retinopathy of prematurity was administered to 220 of 2020 infants (10.9%) in the lower Spo2 target group and 308 of 2065 infants (14.9%) in the higher Spo2 target group (risk difference, -4.0% [95% CI, -6.1% to -2.0%]; RR, 0.74 [95% CI, 0.63 to 0.86], P < .001). Severe necrotizing enterocolitis occurred in 227 of 2464 infants (9.2%) in the lower Spo2 target group and 170 of 2465 infants (6.9%) in the higher Spo2 target group (risk difference, 2.3% [95% CI, 0.8% to 3.8%]; RR, 1.33 [95% CI, 1.10 to 1.61], P = .003). Conclusions and Relevance: In this prospectively planned meta-analysis of individual participant data from extremely preterm infants, there was no significant difference between a lower Spo2 target range compared with a higher Spo2 target range on the primary composite outcome of death or major disability at a corrected age of 18 to 24 months. The lower Spo2 target range was associated with a higher risk of death and necrotizing enterocolitis, but a lower risk of retinopathy of prematurity treatment.

3 Article Gentamicin, genetic variation and deafness in preterm children. 2014

Bitner-Glindzicz, Maria / Rahman, Shamima / Chant, Kathy / Marlow, Neil. ·Genetics and Genomic Medicine, University College London Institute of Child Health and Great Ormond Street Hospital for Children, 30 Guilford Street, London WC1N 1EH, UK. maria.bitner@ucl.ac.uk. ·BMC Pediatr · Pubmed #24593698.

ABSTRACT: BACKGROUND: Hearing loss in children born before 32 weeks of gestation is more prevalent than in full term infants. Aminoglycoside antibiotics are routinely used to treat bacterial infections in babies on neonatal intensive care units. However, this type of medication can have harmful effects on the auditory system. In order to avoid this blood levels should be maintained in the therapeutic range. However in individuals with a mitochondrial genetic variant (m.1555A > G), permanent hearing loss can occur even when drug levels are within normal limits. The aim of the study is to investigate the burden that the m.1555A > G mutation represents to deafness in very preterm infants. METHOD: This is a case control study of children born at less than 32 completed weeks of gestation with confirmed hearing loss. Children in the control group will be matched for sex, gestational age and neonatal intensive care unit on which they were treated, and will have normal hearing. Saliva samples will be taken from children in both groups; DNA will be extracted and tested for the mutation. Retrospective pharmacological data and clinical history will be abstracted from the medical notes. Risk associated with gentamicin, m.1555A > G and other co-morbid risk factors will be evaluated using conditional logistic regression. DISCUSSION: If there is an increased burden of hearing loss with m.1555A > G and aminoglycoside use, consideration will be given to genetic testing during pregnancy, postnatal testing prior to drug administration, or the use of an alternative first line antibiotic. Detailed perinatal data collection will also allow greater definition of the causal pathway of acquired hearing loss in very preterm children.

4 Article Neurological and developmental outcome in extremely preterm children born in England in 1995 and 2006: the EPICure studies. 2012

Moore, Tamanna / Hennessy, Enid M / Myles, Jonathan / Johnson, Samantha J / Draper, Elizabeth S / Costeloe, Kate L / Marlow, Neil. ·Academic Neonatology, UCL Institute for Women's Health, London WC1E 6AU, UK. ·BMJ · Pubmed #23212880.

ABSTRACT: OBJECTIVE: To determine outcomes at age 3 years in babies born before 27 completed weeks' gestation in 2006, and to evaluate changes in outcome since 1995 for babies born between 22 and 25 weeks' gestation. DESIGN: Prospective national cohort studies, EPICure and EPICure 2. SETTING: Hospital and home based evaluations, England. PARTICIPANTS: 1031 surviving babies born in 2006 before 27 completed weeks' gestation. Outcomes for 584 babies born at 22-25 weeks' gestation were compared with those of 260 surviving babies of the same gestational age born in 1995. MAIN OUTCOME MEASURES: Survival to age 3 years, impairment (2008 consensus definitions), and developmental scores. Multiple imputation was used to account for the high proportion of missing data in the 2006 cohort. RESULTS: Of the 576 babies evaluated after birth in 2006, 13.4% (n=77) were categorised as having severe impairment and 11.8% (n=68) moderate impairment. The prevalence of neurodevelopmental impairment was significantly associated with length of gestation, with greater impairment as gestational age decreased: 45% at 22-23 weeks, 30% at 24 weeks, 25% at 25 weeks, and 20% at 26 weeks (P<0.001). Cerebral palsy was present in 83 (14%) survivors. Mean developmental quotients were lower than those of the general population (normal values 100 (SD 15)) and showed a direct relation with gestational age: 80 (SD 21) at 22-23 weeks, 87 (19) at 24 weeks, 88 (19) at 25 weeks, and 91 (18) at 26 weeks. These results did not differ significantly after imputation. Comparing imputed outcomes between the 2006 and 1995 cohorts, the proportion of survivors born between 22 and 25 weeks' gestation with severe disability, using 1995 definitions, was 18% (95% confidence interval 14% to 24%) in 1995 and 19% (14% to 23%) in 2006. Fewer survivors had shunted hydrocephalus or seizures. Survival of babies admitted for neonatal care increased from 39% (35% to 43%) in 1995 to 52% (49% to 55%) in 2006, an increase of 13% (8% to 18%), and survival without disability increased from 23% (20% to 26%) in 1995 to 34% (31% to 37%) in 2006, an increase of 11% (6% to 16%). CONCLUSION: Survival and impairment in early childhood are both closely related to gestational age for babies born at less than 27 weeks' gestation. Using multiple imputation to account for the high proportion of missing values, a higher proportion of babies admitted for neonatal care now survive without disability, particularly those born at gestational ages 24 and 25 weeks.